Matthias P Ebert Selected Research

Matthias P Ebert Research Topics

Disease

32	Neoplasms (Cancer) 11/2022 - 11/2003
14	Colorectal Neoplasms (Colorectal Cancer) 11/2022 - 01/2015
8	Stomach Neoplasms (Stomach Cancer) 10/2021 - 12/2010
5	Adenocarcinoma 11/2022 - 12/2012
4	Fibrosis (Cirrhosis) 12/2022 - 01/2016
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 05/2008
3	Neoplasm Metastasis (Metastasis) 12/2022 - 01/2015
3	Liver Diseases (Liver Disease) 12/2022 - 01/2016
3	Infections 08/2022 - 07/2002
3	Carcinoma (Carcinomatosis) 06/2020 - 03/2008
3	Inflammation (Inflammations) 01/2020 - 01/2009
2	COVID-19 08/2022 - 10/2020
2	Adenoma (Adenomas) 12/2021 - 01/2020
2	Disease Progression 01/2019 - 10/2007
2	Gastritis 04/2015 - 01/2009
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 12/2022
1	Acute Liver Failure (Fulminant Hepatic Failure) 12/2022
1	Liver Failure 12/2022
1	Pathologic Complete Response 11/2022
1	Leukopenia 11/2022
1	Diarrhea 11/2022
1	Hepatocellular Carcinoma (Hepatoma) 01/2022
1	Rectal Neoplasms (Rectal Cancer) 01/2022
1	Fatigue 10/2021
1	Microsatellite Instability 10/2021
1	Turcot syndrome 10/2021
1	Non-alcoholic Fatty Liver Disease 01/2021
1	Hypersensitivity (Allergy) 01/2020
1	Cancer Pain 01/2020
1	Thrombosis (Thrombus) 04/2019
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 03/2019
1	Carcinogenesis 01/2019
1	Leukemia 01/2019
1	Critical Illness (Critically Ill) 01/2018

Drug/Important Bio-Agent (IBA)

9	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2007
7	Proteins (Proteins, Gene)FDA Link 11/2022 - 03/2008
6	Bevacizumab (Avastin)FDA Link 12/2022 - 01/2016
5	Pharmaceutical PreparationsIBA 12/2022 - 05/2014
4	Trastuzumab (Herceptin)FDA Link 11/2022 - 12/2010
3	ErbB Receptors (EGF Receptor)IBA 11/2022 - 03/2008
3	Histones (Histone)IBA 11/2022 - 07/2012
3	ProteomeIBA 12/2010 - 05/2008
2	Capecitabine (Xeloda)FDA Link 12/2022 - 12/2012
2	Antineoplastic Agents (Antineoplastics)IBA 11/2022 - 01/2022
2	Histone Deacetylase InhibitorsIBA 11/2022 - 07/2012
2	Anti-Bacterial Agents (Antibiotics)IBA 08/2022 - 06/2006
2	Growth Differentiation Factor 2IBA 01/2022 - 01/2017
2	Immune Checkpoint InhibitorsIBA 08/2020 - 01/2019
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2019 - 05/2014
2	Messenger RNA (mRNA)IBA 01/2019 - 03/2008
2	PPAR gammaIBA 01/2019 - 03/2008
2	DNA (Deoxyribonucleic Acid)IBA 04/2015 - 01/2015
1	Serum AlbuminIBA 12/2022
1	AlbuminsIBA 12/2022
1	pertuzumabIBA 11/2022
1	Fluorouracil (Carac)FDA LinkGeneric 11/2022
1	Leucovorin (Folinic Acid)FDA Link 11/2022
1	Docetaxel (Taxotere)FDA Link 11/2022
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2022
1	Lysine (L-Lysine)FDA Link 11/2022
1	MethyltransferasesIBA 11/2022
1	Biological ProductsIBA 01/2022
1	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 01/2022
1	atezolizumabIBA 01/2022
1	myotubularinIBA 12/2021
1	Hemoglobins (Hemoglobin)IBA 10/2021
1	Eosine Yellowish-(YS) (Eosin)IBA 10/2021
1	sepantroniumIBA 01/2021
1	Rituximab (Mabthera)FDA Link 10/2020
1	Chemokine ReceptorsIBA 01/2020
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2020
1	ChemokinesIBA 01/2020
1	Angiogenesis InhibitorsIBA 01/2020
1	CCR7 ReceptorsIBA 01/2020
1	AntibodiesIBA 01/2020
1	N 30IBA 01/2020
1	Neutralizing AntibodiesIBA 01/2020
1	Aryl Hydrocarbon Receptor Nuclear TranslocatorIBA 07/2019
1	IpilimumabIBA 03/2019
1	NivolumabIBA 03/2019
1	Transcription Factors (Transcription Factor)IBA 01/2019
1	Cell-Free Nucleic AcidsIBA 01/2019
1	Peptide Hydrolases (Proteases)FDA Link 01/2019
1	CytokinesIBA 01/2019
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019
1	Gemcitabine FDA Link 07/2018
1	130-nm albumin-bound paclitaxelIBA 07/2018

Therapy/Procedure

20	Therapeutics 11/2022 - 07/2002
5	Drug Therapy (Chemotherapy) 11/2022 - 07/2012
4	Immunotherapy 01/2022 - 01/2019
3	Combination Drug Therapy (Combination Chemotherapy) 07/2018 - 07/2012
1	Artificial Respiration (Mechanical Ventilation) 08/2022
1	Molecular Targeted Therapy 01/2022
1	Chemoradiotherapy 01/2022
1	Neoadjuvant Therapy 01/2022
1	Precision Medicine 01/2022
1	Aftercare (After-Treatment) 01/2022
1	Polypharmacy 06/2020
1	Operative Surgical Procedures 06/2020
1	Injections 01/2020